Naruto, Japan

Masafumi Toda

USPTO Granted Patents = 1 


 

Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 13(Granted Patents)


Company Filing History:


Years Active: 2006

Loading Chart...
Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Masafumi Toda: Innovator in Cilostazol Preparation

Introduction

Masafumi Toda is a notable inventor based in Naruto, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the preparation of cilostazol. His innovative approach has the potential to enhance the effectiveness of this important drug.

Latest Patents

Masafumi Toda holds a patent for a cilostazol preparation. This preparation involves incorporating a fine powder of cilostazol into a dispersing and/or solubilizing agent to improve its dispersibility and solubility. The invention addresses the challenge of absorbability of slightly soluble drugs like cilostazol, especially in the lower portion of the digestive tract. By utilizing this method, cilostazol can be effectively absorbed, allowing it to function as a thrombolytic drug or a cerebral circulation improving agent.

Career Highlights

Toda is associated with Otsuka Pharmaceutical Company, Limited, where he continues to work on innovative pharmaceutical solutions. His expertise in drug formulation has contributed to advancements in the treatment of various medical conditions.

Collaborations

Masafumi Toda has collaborated with notable colleagues such as Tadashi Mukai and Yuso Tomohira. Their combined efforts in research and development have furthered the understanding and application of cilostazol in medical treatments.

Conclusion

Masafumi Toda's work in the preparation of cilostazol showcases his dedication to improving drug efficacy and patient outcomes. His innovative contributions are valuable to the pharmaceutical industry and highlight the importance of research in developing effective treatments.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…